The Hôpital Européen Georges-Pompidou is a French hospital located in Paris. The HEGP is under the aegis of the Assistance publique - Hôpitaux de Paris. Opened in 2001, the HEGP is the last-born Parisian hospital resulting from the merger of three older hospitals of the 15th district.

During the past decade, Hôpital Européen Georges Pompidou conducted 388 clinical trials. In the 10-year time frame, 388 clinical trials started and 61 clinical trials were completed, i.e. on average, 15.7% percent of trials that started reached the finish line to date. In the past 5 years, 175 clinical trials started and 45 clinical trials were completed. i.e. 25.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Européen Georges Pompidou" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 90 trials, followed by "UNICANCER" with 27 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 19 trials sponsored, "French Cardiology Society" with 15 trials sponsored and "Pfizer" with 15 trials sponsored. Other sponsors include 425 different institutions and companies that sponsored additional 210 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Européen Georges Pompidou" #1 collaborator was "Ministry of Health, France" with 26 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 15 trials as a collaborator, "European Georges Pompidou Hospital" with 11 trials as a collaborator, "National Cancer Institute, France" with 10 trials as a collaborator and "AstraZeneca" with 9 trials as a collaborator. Other collaborators include 377 different institutions and companies that were collaborators in the rest 291 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Européen Georges Pompidou" are "Colorectal Cancer" (17 trials), "Ovarian Cancer" (16 trials), "Breast Cancer" (14 trials), "Prostate Cancer" (14 trials) and "Pulmonary Embolism" (13 trials). Many other conditions were trialed in "Hôpital Européen Georges Pompidou" in a lesser frequency.

Most popular intervention types in "Hôpital Européen Georges Pompidou" are "Drug" (289 trials), "Other" (93 trials), "Device" (89 trials), "Procedure" (82 trials) and "Biological" (38 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (46 trials), "fluorouracil" (11 trials), "Bevacizumab" (10 trials), "Carboplatin" (9 trials) and "Gemcitabine" (9 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Européen Georges Pompidou" are 505 trials for "All" genders, 61 trials for "Female" genders and 29 trials for "Male" genders.

Currently, there are 208 active trials in "Hôpital Européen Georges Pompidou". 6 are not yet recruiting, 136 are recruiting, 64 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 295 completed trials in Hôpital Européen Georges Pompidou, 1 suspended trials, and 32 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Européen Georges Pompidou, 26 "Phase 1" clinical trials were conducted, 121 "Phase 2" clinical trials and 171 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 140 trials that are defined as “Not Applicable".